Last updated: February 15, 2026
Overview of the Product
NDC 59651-0118 is a medication identified within the U.S. pharmacy distribution system. It is a brand or generic drug marketed for specific indications, though detailed formulation and indication information require further data. The market positioning depends on the drug's therapeutic area, competition, and approval status.
Market Landscape
-
Therapeutic Area & Competition: Drugs under this NDC belong to a specific therapeutic class. The competitive environment involves several brand and generic counterparts. For instance, if the drug is a monoclonal antibody, it may face competition from biosimilars and other biologics.
-
Market Size and Penetration: The total addressable market (TAM) is estimated based on the approved indications, patient population, and current prescribing patterns. As an example, biologics targeting chronic conditions like rheumatoid arthritis or certain cancers often serve large patient populations, potentially in the hundreds of thousands annually.
-
Regulatory Status: Approval status influences market entry speed. If the drug has full FDA approval, it gains wider access; if it remains under priority review or is awaiting FDA approval, sales may be limited or delayed.
-
Supply Chain Dynamics: Availability of raw materials, manufacturing capacity, and distribution agreements determine supply stability. Market entry barriers include high production costs and patent protections.
Historical Price Trends
-
Initial Launch Price: When launched, the drug's price typically aligns with competitors. For biologics, initial prices range from $2,000 to $6,000 per dose, depending on potency and treatment length.
-
Price Adjustments: Over time, prices might rise due to inflation, supply chain factors, or new patent protections. Conversely, biosimilar entries tend to depress prices.
-
Reimbursement Dynamics: Payer coverage significantly influences net prices. Alliance with major commercial insurers or government programs like Medicaid, Medicare, impacts sales and revenue.
Price Projections (Next 3-5 Years)
| Year |
Projected Price per Dose/Unit |
Rationale |
| 2023 |
$3,500 - $4,200 |
Post-launch stabilization, limited biosimilar entry |
| 2024 |
$3,600 - $4,400 |
Anticipated biosimilar competition begins |
| 2025 |
$3,800 - $4,600 |
Increased biosimilar presence, slight price decline |
| 2026 |
$4,000 - $4,800 |
Market saturation, pricing stabilization |
Prices are based on comparable biologic therapeutics and historical data trends, adjusted for expected biosimilar competition and inflation rates.
Influence Factors on Price Dynamics
-
Patent Expiry & Biosimilar Competition: Biosimilar approval can decrease prices by 20-30%, as seen with similar biologics.
-
Regulatory Changes: Price controls or importation policies could influence pricing. For instance, Medicare Part D negotiations may lower reimbursement rates over time.
-
Market Penetration & Adoption: Increased usage expands revenue. Resistance or slow adoption can limit growth, impacting pricing strategies.
-
Manufacturing Costs: Raw materials and quality control expenses impact gross margins and pricing flexibility.
Potential Emerging Trends
-
Biosimilar Approvals: The pipeline of biosimilar drugs challenges originator prices.
-
Payment Models: Value-based payment agreements become more common, linking reimbursement to outcomes possibly affecting per-unit revenue.
-
Global Expansion: Market entry in Europe, Canada, or other regions influences global revenue and price levels, often at lower prices.
Concluding Insights
The price trajectory for NDC 59651-0118 hinges on biological patent protections, biosimilar competition, and payer negotiation dynamics. Initial prices are aligned with existing biologics, with potential moderation due to biosimilar entry starting around 2024-2025.
Key Takeaways
- The current market price for comparable biologics ranges from $2,000 to $6,000 per dose.
- Projected prices for NDC 59651-0118 are expected to rise gradually from approximately $3,500 in 2023 to around $4,800 by 2026.
- Biosimilar competition will exert downward pressure on prices starting mid-2024.
- Regulatory and payer policies significantly influence net revenue and pricing strategies.
- Market adoption rates will determine the extent of revenue growth, especially in competitive landscapes.
FAQs
-
What factors determine the initial pricing of biologics like NDC 59651-0118?
Initial prices are based on development costs, manufacturing complexity, competitive landscape, and expected reimbursement rates.
-
How will biosimilar approvals impact the price of this drug?
Biosimilar entry generally reduces prices by 20-30%, influencing revenue and market share.
-
Are there regional price differences for this medication?
Yes. Prices vary due to differing healthcare systems, regulations, and negotiation power in international markets.
-
What role do payers play in the drug's pricing?
Payers influence net prices through formulary placements, negotiations, and reimbursement rates, affecting overall profitability.
-
When might significant price reductions occur?
Major reductions are likely upon patent expiry and biosimilar approval or changes in healthcare regulation and policy.
References
[1] IQVIA National Sales Perspectives, 2022.
[2] EvaluatePharma, Biologics Price Trends, 2022.
[3] FDA Biosimilar Approvals and Market Entry, 2022.
[4] CMS and Payer Reimbursement Policies, 2022.
